Olanzapină Teva (Olanzapine)

Olanzapine, the active ingredient in Olanzapină Teva, is an atypical antipsychotic presented as an oral formulation for buccal, oral, and sublingual use. It is prescribed for the treatment of schizophrenia and bipolar I disorder in adult patients, helping to control psychotic symptoms and mood instability.

GNH USA supplies Olanzapină Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution with comprehensive regulatory support.

Olanzapine is used in the management of psychiatric disorders that involve dopamine and serotonin dysregulation.

Schizophrenia: reduces psychotic symptoms and lowers relapse risk. Bipolar I disorder (manic episodes): stabilizes mood and decreases manic symptoms. Maintenance therapy: helps prevent recurrence of psychotic or mood episodes.

Common Side Effects: - Weight gain: increased body mass and appetite. - Sedation: drowsiness or fatigue. - Dry mouth: reduced salivation. - Constipation: decreased bowel movements.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe drop in white blood cells. - Severe hyperglycemia: marked increase in blood glucose levels. - Tardive dyskinesia: involuntary, repetitive movements. - Myocarditis: inflammation of the heart muscle.

Olanzapină Teva requires careful monitoring and adherence to safety guidelines.

Monitor metabolic parameters: regularly assess weight, glucose, and lipid levels. Observe for extrapyramidal symptoms: watch for movement disorders or rigidity. Evaluate cardiac status: perform ECG if risk factors for QT prolongation exist. Review hepatic function: adjust use in patients with liver impairment. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Olanzapină Teva may interact with several concomitant medications.

Major Interactions (Avoid): - Concomitant antipsychotics: increased risk of CNS depression. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise olanzapine plasma levels. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine): may lower olanzapine concentrations. - Antihypertensives: potential enhancement of orthostatic hypotension. - Anticholinergic agents: may increase anticholinergic burden.